Axsome Therapeutics Reports Successful Phase III Clinical Trial Program Treating Alzheimer Disease Agitation

Posted on by admin

Data from the Phase III trial program found that AXS-05 demonstrated statistically significant efficacy in treating Alzheimer disease agitation.

Leave a Reply

Your email address will not be published. Required fields are marked *